

iScience, Volume 25

Supplemental information

Partial prevention of glucocorticoid-induced osteocyte deterioration in young male mice with osteocrin gene therapy

Courtney M. Mazur, Christian D. Castro Andrade, Nicha Tokavanich, Tadatoshi Sato, Michael Bruce, Daniel J. Brooks, Mary L. Boussein, Jialiang S. Wang, and Marc N. Wein




Figure S1: Effects of glucocorticoids and CNP/Ostn on integrin β 3 expression *in vitro*, related to Figure 1.

(A) Ocy454 cells were treated with dexamethasone at the indicated concentrations for 24 hours. Expression of *Itgb3* was measured by RT-qPCR and presented relative to *Actb*. $n=3$. $*p<0.05$ by Tukey's multiple comparisons tests.

(B) Integrin β 3 (CD61) surface labeling in Ocy454 cells is reduced following 24 hours of dexamethasone (Dex) treatment. Plots show representative histograms and gating strategy used for flow cytometry.

(C-E) Ocy454 cells were pretreated with CNP (100 nM), CNP+Ostn (100 nM + 500 nM), or vehicle for one hour, followed by 24 hours dexamethasone (1 μM) treatment. Dexamethasone-induced reduction in median fluorescence intensity (MFI) of CD61 labeling is shown for three independent experiments in (C), for one representative experiment with three biologic replicates in (D), and for one sample per condition in (E). $*p<0.05$ by Sidak's multiple comparisons tests.

All error bars show \pm SD.




Figure S2: Systemic effects of AAV8-Ostn and prednisolone in mice, related to Figures 2-5.

(A) Hepatic expression of *Ostn* mRNA was measured relative to *Actb* 1, 3, and 7 days after intraperitoneal injection of AAV8-Ostn in C57BL/6J mice (n=3).

(B) Hepatic expression of *Ostn* mRNA was measured relative to *Actb* 35 days after intraperitoneal injection of AAV8-Ostn or AAV8-Control and 28 days after placebo or prednisolone pellet implantation in FVB mice. n=8-10. *p<0.05, ***p<0.001 relative to corresponding AAV8-control group by Sidak's multiple comparisons tests.

(C-D) Mice were weighed weekly starting 2 weeks prior to GC pellet implantation, and statistical comparisons were performed at the end of the experiment. n=8-10. *p<0.05 compared to corresponding placebo group by Sidak's multiple comparisons tests.

All error bars show +/- SD.




Figure S3: Prednisolone-induced changes in bone gene expression, related to Figure 2. Gene expression was measured relative to *Actb* in humeri after 28 days of prednisolone or placebo treatment in (A) AAV8-Control (n=7-9) and (B) AAV8-Ostn-treated (n=8) mice. Error bars show +/- SD.




Figure S4: Osteocrin-induced changes in gene expression, related to Figure 2, Figure S1, Figure S2.

(A) Expression of Erk1/2-responsive gene *Fos* was measured in marrow-depleted humeri and normalized to *Actb* 35 days after intraperitoneal injection of AAV8-Ostn or AAV8-Control. $n=7-10$. p value shown compared to corresponding AAV8-Control group by Sidak's multiple comparisons test. Error bars show \pm SD.

(B) *Fos* expression in marrow-depleted humeri (normalized to *Actb*) is plotted relative to hepatic *Ostn* expression (normalized to *Actb*) for each mouse ($R^2 = 0.15, p=0.026, n=32$).

(C) Expression of *Itgb3* was measured in marrow-depleted humeri and normalized to *Actb* 35 days after intraperitoneal injection of AAV8-Ostn or AAV8-Control. $n=7-10$. $*p<0.05$ compared to corresponding AAV8-Control group by Sidak's multiple comparisons tests. Error bars show \pm SD.

Table S1: Oligonucleotide primer sequences, related to STAR Methods.

Actb Fwd	CCT CTA TGC CAA CAC AGT GC
Actb Rev	ACA TCT GCT GGA AGG TGG AC
Ostn Fwd	AGT TTG GGA TAA GCT GCA GG
Ostn Rev	AGT CCA CAG AGA ATG CCT TTC
Sp7 Fwd	CCT CTC CCT TCT CCC TCT C
Sp7 Rev	CTG GAG CCA TAG TGA GCT TC
Gilz Fwd	TGA CTG CAA CGC CAA AGC
Gilz Rev	CTG ATA CAT TTC GGT GTT CAT GGT T
Acp5 Fwd	CCA TTG TTA GCC ACA TAC GG
Acp5 Rev	ACT CAG CAC ATA GCC CAC AC
Ctsk Fwd	CAT GGT GAG CTT TGC TCT GT
Ctsk Rev	CCG AGA GAT TTC ATC CAC CT
Mmp13 Fwd	TGT GTT TGC AGA GCA CTA CT
Mmp13 Rev	CTA AGC CAA AGA AAG ATT GCA TTT C
Fos Fwd	TGC GTT GCA GAC TGA GAT TG
Fos Rev	ATC TCC TCT GGG AAG CCA AG
Bglap Fwd	CGC TCT GTC TCT CTG ACC TC
Bglap Rev	GAC TGA GGC TCC AAG GTA GC
Sost Fwd	GCC TCA TCT GCC TAC TTG TG
Sost Rev	CTG TGG CAT CAT TCC TGA AG
Dkk1 Fwd	GAG GGG AAA TTG AGG AAA GC
Dkk1 Rev	AGC CTT CTT GTC CTT TGG TG
Itgb3 Fwd	AGG ATG CGA GCG CAG TG
Itgb3 Rev	TGG TAC AGA TGT TGG ACT CTC C